Gavi Board starts framing Alliance’s approach to 2021-2025 period

Milestones :: Perspectives
 
 
Gavi Board starts framing Alliance’s approach to 2021-2025 period

Gavi Board approves in principle a set of new and expanded vaccine programmes.
Geneva, 29 November 2018 – The Gavi Board has made a series of decisions that will help shape the Alliance’s approach for the period 2021-2025 during a two-day meeting in Geneva’s Global Health Campus. The Board will adopt the 2021-2025 strategic goals at its next meeting in June 2019.

“The Board had extensive discussions on Gavi’s future direction which will lead to intense work over the coming months to develop a strategy for the 2021-2025 period – the fifth in Gavi’s existence,” said Dr Ngozi Okonjo-Iweala, Gavi Board Chair. “The global landscape has changed fundamentally since Gavi was created in 2000 and the Alliance is changing with it. While for Gavi the core focus remains on its current mission of accelerating access to vaccines and increasing equitable coverage in the world’s poorest countries, Gavi is also adapting to meet the challenges of the future.”

As part of its Vaccine Investment Strategy (VIS), the Gavi Board approved a future investment in six new and expanded vaccine programmes, contingent on the final parameters of Gavi’s 2021-2025 strategy (Gavi 5.0) and sufficient funding being made available after Gavi’s next replenishment. Following a thorough evaluation of current and future vaccines, the final VIS prioritised:

:: hepatitis B birth dose – to prevent chronic hepatitis B virus (HBV) infection, which develops in as many as 90% of infants infected with HBV at birth or in the first year of life and can lead to liver cancer,

:: diphtheria, pertussis & tetanus containing boosters – given at 12-24 months, 4-7 years and 9-15 years, these three boosters offer continued protection from those diseases beyond the primary series administered in the first year,

:: oral cholera vaccine (OCV) – to proactively reduce incidence of a disease that mainly affects poor and marginalised people,

:: human rabies vaccine for post-exposure prophylaxis – to provide equitable access to human rabies prevention following a suspected dog bite,

:: meningococcal conjugate vaccine – multivalent A,C,W-containing vaccine to expand serogroups protection beyond meningitis A,

:: and respiratory syncytial virus (RSV) – to prevent one of the most common causes of bronchiolitis and pneumonia in children under 1 year of age.

“Unlike previous vaccine investment strategies, these vaccines will involve building new delivery platforms which will strengthen primary healthcare as a whole,” said Dr Berkley. “This life-course immunisation approach can help lay the foundation for strengthening primary healthcare as a whole by providing more moments in which a child, adolescent or adult is in contact with health workers.”…